FLT3 inhibitors – an ideal strategy for treating FLT3-mutated AML
Can transplant quality be improved by training medical personnel?
T-Cell engaging treatment in AML
The utility of measurable residual disease (MRD) assessment in acute myeloid leukemia (AML)
Gert J. Ossenkoppele
Why venetoclax is a promising new drug for CLL